Vaccination Against West Nile Virus

西尼罗河病毒疫苗接种

• 批准号: 6777091
• 负责人: Raymond Allen Koski
• 金额: $ 37.01万
• 依托单位: L2 DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-15 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6777091
• 关键词: SDS polyacrylamide gel electrophoresis; West Nile virus; active immunization; antibody titering; dosage; drug screening /evaluation; enzyme linked immunosorbent assay; horses; laboratory mouse; neutralizing antibody; polymerase chain reaction; protein purification; recombinant virus; serology /serodiagnosis; vaccine development; vector vaccine; viral vaccines; virus antigen; virus envelope

DESCRIPTION (provided by applicant): A commercially viable recombinant subunit vaccine to prevent West Nile virus infection is the overall objective of this project. West Nile virus was isolated for the first time in North America in 1999. In less than three years, the geographical distribution of the virus expanded dramatically in the United States. A vaccine will be an important complement to other public health measures as this emerging pathogen becomes endemic in this continent. Phase I research studied immunogens based on the envelope protein of a U.S. West Nile virus isolate. We prepared recombinant protein and synthetic peptide antigens, and initiated immunization studies. Mice were vaccinated with the recombinant antigens, antibody responses were evaluated, and protective immunity was characterized. Phase II experiments will vaccinate horses with a promising candidate vaccine, and demonstrate that vaccination elicits protective antibodies. Experiments are designed to elicit high titer antibodies using our recombinant envelope protein antigen with aluminum hydroxide adjuvant. Subsequent experiments will determine if antibodies induced in horses can: (1) neutralize West Nile virus in vitro; (2) protect passively immunized mice from West Nile virus. This project will provide veterinarians, clinicians and public health officials with new means to manage West Nile virus outbreaks.

描述（由申请人提供）：本项目的总体目标是开发商业上可行的重组亚单位疫苗来预防西尼罗河病毒感染。 1999年，西尼罗河病毒首次在北美分离出来。不到三年的时间，该病毒的地理分布在美国急剧扩大。 随着这种新出现的病原体在非洲大陆流行，疫苗将成为其他公共卫生措施的重要补充。 第一阶段研究研究了基于美国西尼罗河病毒分离株包膜蛋白的免疫原。 我们制备了重组蛋白和合成肽抗原，并启动了免疫研究。 用重组抗原对小鼠进行疫苗接种，评估抗体反应，并表征保护性免疫。 第二阶段实验将为马匹接种一种有前景的候选疫苗，并证明疫苗接种会引发保护性抗体。 实验旨在使用我们的重组包膜蛋白抗原和氢氧化铝佐剂来引发高滴度抗体。 后续实验将确定在马中诱导的抗体是否可以：（1）在体外中和西尼罗河病毒； (2)保护被动免疫小鼠免受西尼罗河病毒的侵害。 该项目将为兽医、临床医生和公共卫生官员提供管理西尼罗河病毒爆发的新方法。

项目成果

Serum antibodies to West Nile virus in naturally exposed and vaccinated horses.

• DOI: 10.1099/jmm.0.47849-0
• 发表时间: 2008-09
• 期刊: JOURNAL OF MEDICAL MICROBIOLOGY
• 影响因子: 3
• 作者: Magnarelli, Louis A.;Bushmich, Sandra L.;Anderson, John F.;Ledizet, Michel;Koski, Raymond A.
• 通讯作者: Koski, Raymond A.